A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

July 24, 2017

Study Completion Date

July 24, 2017

Conditions

Healthy Participants

Interventions

DRUG

TAK-954

TAK-954 Infusion

DRUG

Itraconazole

Itraconazole Capsule

Trial Locations (1)

Pharmaceutical Research Associates, Inc., Lenexa